Glioblastomas (GBM) are among the most aggressive and therapy-resistant tumors of the central nervous system and present both clinicians and researchers with immense challenges. Despite significant advances in diagnostics and an improvement in standard therapy, which usually consists of surgical resection, subsequent radiotherapy and the administration of temozolomide, the survival prospects are still unsatisfactory. This is mainly due to the pronounced resistance, the complex tumor heterogeneity and the immunomodulating properties of glioblastoma cells and their microenvironment.
You May Also Like
- Pathogenesis, diagnostics and therapeutic interventions
Sarcopenia in Parkinson’s disease
- Casuistry
63-year-old with tracheobronchopathia osteoplastica
- 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline
Management of acute coronary syndrome
- Pustular psoriasis
What is known about inflammatory mechanisms in PPP and GPP?
- Diabetes-related cardiovascular diseases
Ferroptosis: key mechanisms and novel therapeutic approaches
- Atrial fibrillation
What’s new with the “pace-and-ablate” strategy?
- De-escalation strategies
De-escalation strategies – less is more
- Pathogens in the brain